Compare UVV & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UVV | BBNX |
|---|---|---|
| Founded | 1886 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2025 |
| Metric | UVV | BBNX |
|---|---|---|
| Price | $52.29 | $29.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $28.09 |
| AVG Volume (30 Days) | 176.9K | ★ 618.5K |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | ★ 6.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.44 | N/A |
| Revenue | ★ $2,987,411,000.00 | $88,570,000.00 |
| Revenue This Year | $3.21 | $52.13 |
| Revenue Next Year | $1.02 | $36.16 |
| P/E Ratio | $11.77 | ★ N/A |
| Revenue Growth | 3.01 | ★ 67.01 |
| 52 Week Low | $49.40 | $8.89 |
| 52 Week High | $67.33 | $32.71 |
| Indicator | UVV | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 55.31 |
| Support Level | $52.30 | $27.87 |
| Resistance Level | $53.25 | $31.51 |
| Average True Range (ATR) | 0.81 | 2.09 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 23.91 | 47.23 |
Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.